This 2013 review discusses advancements in antiobesity pharmacotherapy, focusing on newly approved drugs and emerging therapeutic targets. It highlights the approval of lorcaserin, a selective 5-HT₂C receptor agonist that promotes satiety through hypothalamic pathways, and phentermine/topiramate ER, a combination therapy that suppresses appetite and enhances satiety via central nervous system
